Acute myeloid leukemia (AML) exhibits extensive heterogeneity in therapeutic response, even in patients sharing similar characteristics, indicating the inadequacy of currently used biopsy-based prognostic tools. There is a critical need for non-invasive quantitative imaging modality specific to AML, which is able to assess this disease in the whole body, including in extramedullary organs and to longitudinally monitor treatment response. CD33, an accepted AML biomarker is expressed on more than 85-90% of blast cells and Mylotarg (anti-CD33-ADC) is FDA approved immunotherapy for AML. In this preclinical study using anti-human CD33 mAb ( 64 Cu-DOTA-anti-CD33), a CD33 PET-CT imaging modality was developed that detected AML with high sensitivity and specificity. The approach also indicated spatial heterogeneity in leukemic disease, dependent on disease burden, which warrants caution in analyzing results from single point bone marrow biopsies. Therefore, this imaging modality can be used to non-invasively detect AML in humans and also monitor treatment response, an unmet clinical need.
Translational Relevance
Acute myeloid leukemia (AML) exhibits extensive heterogeneity in therapeutic response, even in patients sharing similar characteristics, indicating the inadequacy of currently used biopsy-based prognostic tools. There is a critical need for non-invasive quantitative imaging modality specific to AML, which is able to assess this disease in the whole body, including in extramedullary organs and to longitudinally monitor treatment response. CD33, an accepted AML biomarker is expressed on more than 85-90% of blast cells and Mylotarg (anti-CD33-ADC) is FDA approved immunotherapy for AML. In this preclinical study using anti-human CD33 mAb ( 64 Cu-DOTA-anti-CD33), a CD33 PET-CT imaging modality was developed that detected AML with high sensitivity and specificity. The approach also indicated spatial heterogeneity in leukemic disease, dependent on disease burden, which warrants caution in analyzing results from single point bone marrow biopsies. Therefore, this imaging modality can be used to non-invasively detect AML in humans and also monitor treatment response, an unmet clinical need.
Introduction
Acute myeloid leukemia (AML) is a highly aggressive hematopoietic malignancy with an extremely poor prognosis as reflected by an overall 5-year survival rate of 40%-45% in young adults and <10% in the elderly (>65 years of age) (1) . Research over the past decades has helped us understand the pathobiology, classification and genomic landscape of the disease, which has resulted in improving current treatment options. Despite advances, the prognosis for elderly patients who account for the majority of new AML cases remains discouraging (2) .
More than 70% of elderly AML patients (> 65 years old) will die of their disease within 1 year of diagnosis and treatment (3) . Therefore, new diagnostic and therapeutic approaches are necessary to improve outcomes.
Currently, the diagnostic criteria for AML is the presence of ≥20% blasts in the bone marrow or peripheral blood (4) . AML diagnosis and prognosis are currently achieved by single-point bone marrow biopsies (iliac crest) followed by cytogenetics and mutation analysis.
However, the iliac crest may not always be accurately representative of disease distribution within the entire body, particularly in the context of extramedullary disease, which is common in AML. Hence, there is need for new diagnostic tools that are non-invasive, specific and sensitive to AML in the whole body, including extramedullary organs, and useful to longitudinally monitor disease and treatment response.
CD33 or SIGLEC3 is a cell surface marker found on myeloid stem cells, monoblasts, myeloblasts, monocytes/macrophages, and granulocytic precursors. However, CD33 is not expressed on erythrocytes, platelets, B-cells, T-cells, or NK cells, making it a suitable myeloid marker and therefore commonly used in the diagnosis of AML. CD33 has been shown to be expressed in more than 85% of AML cells (blasts) (5) , and an increased level of CD33 has been correlated with poor survival (6) . Also, an anti-CD33 antibody drug conjugate (ADC) (Mylotarg) is FDA approved immunotherapy for AML. Therefore, we hypothesized that an anti-CD33 monoclonal antibody (mAb) would be an ideal candidate for immuno-positron emission tomography (PET) imaging of AML.
PET and computed tomography (CT) is an important imaging modality used in nuclear medicine. PET has an advantage in providing physiological and biochemical information to identify normal versus malignant lesions, but lacks anatomical details. However, CT provides high-resolution images with substantial anatomical details but lacks physiological information.
Therefore, in the past decades, the two imaging modalities have been integrated forming PET-CT, which provides accurate diagnosis with anatomical details which is crucial in biopsy and focal radiotherapy (7) .
The primary goal of this study was to evaluate an anti-CD33 mAb as a diagnostic imaging marker of AML in a preclinical mouse model. For proof of concept, we first used the murine 64 Cu-DOTA-anti-CD33 (clone p67.6) mAb for immuno-PET-CT imaging of CD33 + AML cells (diagnostic) in a mouse xenograft model. However, besides detecting AML, this imaging modality interestingly also provided information about the spatial distribution of disease in the whole body. Then, with a translational objective, we produced a humanized anti-CD33 monoclonal antibody (clone Hu-M195), confimed similar CD33 PET-CT imaging of AML, and explored its therapeutic potential.
Materials and Methods

Antibody
Murine anti-human CD33 clone p67.6 is an IgG1 kappa monoclonal antibody (mAb) that targets human CD33-positive cells of the myeloid lineage (8, 9) . The hybridoma was produced in a hollow fiber bioreactor and purified by Protein G and cation exchange chromatography.
Anti-human CD33 (Clone WM 53, # 555450) was obtained from BD Biosciences. Anti-human CD45 (clone: 2D1, # 368516) was obtained from BioLegend, San Diego, CA.
Humanized anti-CD33
The murine anti-CD33 M195 mAb was humanized by CDR grafting to reduce human antimouse antibody responses (10, 11) . The scFv was reformatted to a human IgG1 antibody by cDNA synthesis, transiently expressed in HEK293 cells and purified by Protein A chromatography.
Anti-human CD33 antibody DOTA and 64 
Cu conjugation
The mouse and humanized anti-human CD33 mAb were conjugated with the metal chelator 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (NHS-DOTA; Macrocyclics, Dallas, TX) as previously described (12) . The detailed methods are provided in supplemental method.
Cell lines
Human AML cells (HL60, MV4-11, Kg1a) and multiple myeloma (MM) cells MM.1S, Daudi cells were used in this study and cultured using standard tissue culture condition. The use of human samples were in accordance and approved by institutional review borad and the informed consent was obtained from patients or guardians in accordance with the Declaration of Helsinki. Detailed information about the cells and culture conditions are described in the supplementary methods section.
Flow cytometry
Flow cytometry was used to analyze CD33 and CD45 expression in human AML (MV4-11, HL 60 and Kg1a) and multiple myeloma cells (MM1S) using mouse anti-human CD33 and CD45
antibodies. Staining and flow cytometry analysis was performed as per standard protocols. Data were acquired from a BD Fortessa cytometer and analyzed in FlowJo V 10.0 software. 64 Cu-anti-CD33-DOTA PE-CT imaging and biodistribution of MV4-11 AML bearing mice and no-leukemic control mice is representative of atleast 2 independent experiements (n=5).
microPET-CT imaging and biodistribution studies
Mouse AML models: immunodeficient (NSG)
All animal experiments were carried out in accordance to the guidelines of Institutional Animal
Care and Use Committee (IACUC). The NSG (NOD-scidIL2Rg null ) mice were purchased from
The Jackson laboratory and were in bred in city of hope animal breeding facility. The NSG mice were treated with 1-2 Gy radiation 24 hours before transplant as a preconditioning regime to ensure faster engraftment. Human AML and MM cells (1-2 x 10 6 cells) were injected via tail vein, and engraftment was determined using bioluminescent imaging (BLI) 7-10 days posttransplant. Biodistribution and 64 Cu-DOTA-anti-CD33 mAb imaging studies, immunotherapy interventions were performed around 2-3 weeks post-transplant.
Murine and humanized anti-CD33 mAb blood pharmakokinetics
Humanized anti-CD33-DOTA mAb was radiolabeled as mentioned before with 111 In (Triad, Isotope, Los Angeles, CA). The blood activity clearance of murine and humanized 111 In-DOTA-anti-CD33 mAb was tested by collecting blood from tail veins at different points post injections (0, 2, 4, 24, 48, 72 h) and using a gamma counter. The detailed method is described in supplemental section.
Humanized anti-CD33 and secondary (2º) Ab-ADC in vitro and in vivo
The therapeutic potential of humanized anti-CD33 mAb as an ADC was evaluated indirectly using anti-human IgG (Fc) 2º Ab conjugated to monomethyl auristatin E, (MMAE) (Moradec, LLC, San Diego, CA). The in vitro cytotoxicity assay was performed using a 1:1 molar ratio of anti-CD33 and 2º-ADC antibody. The primary and secondary antibody were first allowed to bind (~15 min) in complete IMDM medium and was then added to cells and incubated at 37C, 5% CO 2 . The cytotoxicity was assayed after 5 days by measuring Annexin V and PI staining in these cells. The antibody amount used ranged from 1 ng-2.5 µg. As control, CD33 -Daudi cells (multiple myeloma) and secondary Ab-ADC alone (1 µg) were used.
For in vivo study, 2.5 µg of humanized anti-CD33 antibody and 2.5 µg of secondary Ab-ADC were mixed, incubated for 15 min at 4ºC, and then resuspended in 100 µl of PBS 0.1% BSA and retro-orbitally injected into mice bearing MV4-11 leukemia on day 0 and day 3. As controls, leukemic mice were untreated or given secondary Ab-ADC alone. Disease progression was monitored using BLI at indicated time points. The whole body of the mouse was contoured, and average BLI intensity (photons/s) for each group was plotted at different time points.
Humanized anti-CD33 radioimmunotherapy (CD33-RIT)
Humanized anti-CD33-DOTA mAb was radiolabeled as mentioned before with 
Statistical analysis
Statistical analysis was performed using ANOVA and the students-t test. The Pearsons correlation coefficients were calculated assuming a Gaussian distribution. The difference was considered significant when the p value was <0.05. All graphs and statistical analysis were generated using GraphPad Prism software V 7.2.
Other materials and methods
Detailed methods for anti-human CD33 (clone P67.6 Hu-M195) mAb DOTA and 
Results
Generation of 64 Cu-DOTA anti-CD33 (p67.6) Monoclonal Antibody
For use as a immunoPET tracer, the anti-human CD33 mAb, mouse hybridoma P67.7, was produced, purified, conjugated to the metal chelate DOTA and radiolabeled with 64 Cu.
Coomassie stained SDS-PAGE gel electrophoresed under reducing conditions shows the purity, 
CD33 cell surface expression in AML cells
The murine DOTA-anti-CD33 mAb was tested for binding and specificity by flow cytometry using CD33 positive MV4-11, HL-60 cells, Kg1a, and the CD33-negative MM.1S-GFP cells. 64 Cu-DOTA-anti-CD33 mAb immuno PET-CT in vivo imaging was performed in NSG mice bearing CD33 + AML cells, CD33-MM cells, and non-leukemic control mice. Mice were injected with 64 Cu-DOTA-anti-CD33 mAb (100 µCi/10 µg) 24-48h prior to PET imaging. As an additional control for specificity, the 64 Cu-DOTA-anti-CD33 mAb (100 µCi/ 10 µg) + 500 µg of unlabeled DOTA-anti-CD33-mAb (1:50) were injected into mice bearing CD33 + AML cells. Bioluminescent imaging of AML and MM.1S cells in NSG mice was carried out 24 hrs prior to 64 Cu-DOTA-anti-CD33 mAb injections. The engraftment of AML and MM cells was also measured in the femur, L-spine, and spleen using flow cytometry upon harvesting tissues/organs after imaging and biodistribution studies. PET-CT images (sagittal and coronal)
PET-CT imaging and biodistribution of CD33 + AML cells in mouse model
clearly show CD33 + activity only in MV4-11 AML mice, but not in mice given cold anti-CD33, mice with MM.1S, and non-leukemic control mice (Fig. 1A, B) , while the BLI images of the respective mice shows engraftment (Fig. 1C ). CD33 + PET activity was detected in the epiphysis/metaphysis of femur, tibia, and humerus; L-spine; and pelvic bone in CD33 + MV4-11 bearing mice (Fig. 1D) . Although BLI and flow cytometry indicated high levels of myeloma cells in MM.1S bearing mice, there was no detectable CD33 + activity; similarly, the mice injected with cold unlabeled CD33 antibody showed no CD33 + PET signal, suggesting high specificity ( Fig. 1 A-C) .
Biodistribution studies were carried out in mice from respective groups by harvesting different organs/tissue 24-48h post injection of the 64 Cu-DOTA-anti-CD33 mAb, and the activity was measured using a gamma counter. The % ID/g of tissue/organs was plotted to determine the activity. The PET-signal was similar in all groups for blood, liver, lung, heart, muscle, intestine and kidney ( Fig. 2A,B) . However, the % ID/g was particularly high in bones (Femur, humerus, tibia and lumber spine) in CD33 + bearing MV4-11 AML mice, but not in CD33 -MM mice, cold-blocked AML mice, or control non-leukemic mice (Fig. 2C) . Therefore, MV4-11 AML mice had CD33 + activity in the femur, tibia, L spine and humerus. 64 Cu-DOTA-anti-CD33
targeting was validated independently using a second AML cell line, HL-60, and similar biodistribution results were obtained (Fig. 2D, E) .
The sensitivity and specificity were calculated from biodistribution of the 64 Cu-DOTA-anti-CD33 mAb injected AML mice. The ROC curves showing sensitivity vs 100-specificity for biodistribution data from the femur show high sensitivity (~95%) and specificity (100%) (Fig.   3A) .
Further, the femur and L-spine of AML bearing mice were contoured in PET-CT images. The extent of engraftment from these bones was then determined by flow cytometry of human CD45 + cells/ MV4-11-RFP. A high correlation was observed between PET-CT signals and percent engraftment (R 2 value for femur and L-spine is 0.9854 and 0.8027, respectively) ( Fig. 3 B, C). Additionally, the femur of AML bearing mice was contoured both in BLI and PET-CT images, and a high correlation were observed between BLI and PET-CT signals (R 2 = 0.9262) (Fig. 3D) . However, spatial localization was evident in PET-CT in comparison to BLI images, which were diffuse.
Spatial heterogeneity in AML in vivo
Besides detecting a CD33 + specific signal, anti-CD33 PET-CT imaging also indicated the spatial heterogeneity of AML. CD33 + PET activity was significantly heterogeneous within the femur; for example, the distal and proximal femur showed higher CD33 activity compared to the long bone area in mice with low leukemia burden; however, heightened activity in the long bone was observed when leukemic burden increased (Fig. 4A) . A similar localization pattern was seen in other bones including the tibia, humerus and L-spine (Fig. 1D ). CD33 activity was mostly concentrated in the proximal/distal end of the bone. Further supporting the spatial distribution of AML, in the L-spine (Fig. 4B ) at areas of low leukemic burden (5-10%), the disease is strongly localized to one of the segments (L1-L5) of the L-spine. However, with increasing leukemic burden (>15%) the leukemia is distributed across the L-spine and can be seen even on the T-spine, which was initially undetectable in the low leukemia group (Fig. 4B) , suggesting a preferential niche for AML during the early stages of disease progression.
Humanized anti-CD33 antibody detects CD33 AML
After validating the use of CD33 mAb as an imaging agent, with the intent of translating this promising technology to humans, we produced a humanized anti-CD33 mAb, as described in the methods. The radiolabeling, immunoreactivity and stability (48h, in vivo) were analyzed as mentioned for the murine version (Supplemental Figure S 3A-D) . We tested the humanized 64 Cu-DOTA anti-human CD33 mAb immunoreactivity and found that it bound specifically to The humanized 64 Cu-DOTA anti-human CD33 mAb PET-CT images (Fig. 5A,B) clearly show targeting of AML cells to the skeletal system similarly to the murine Ab, and the respective BLI image showing AML engraftment (Fig. 5C ). As in the murine Ab PET imaging, humanized mAb also signaled CD33 + PET activity localized to the epiphysis/diaphysis of the bones, which was dependent on disease burden, indicating spatial heterogeneity (Fig. 5D ). The humanized Ab also revealed CD33 + activity in the spleen of mouse, with ~20% AML engraftment (Fig. 5A) , suggesting its ability to detect extramedullary disease. Biodistribution studies were carried out in mice from respective groups as mentioned before. There was no significant difference in PET signals in both groups in the heart, lung, muscle and kidney (Fig.   5E) ; however, the signal was significantly reduced in the blood while increased in liver. Also, noticably, there was reduction of the PET signal in the heart of the AML-bearing mice with the humanized antibody in comparison to the murine Ab, which may be due to lower blood activity. The % ID/g was particularly high in bones in CD33 + bearing AML mice, but not in control non-leukemic mice (Fig. 5F ). Furthermore, the humanized mAb showed ~3-4 times higher CD33 + activity in bones than with murine mAb (Supplemental Figure S 4D ).
Humanized anti-CD33 mAb show therapeutic potential
Additionally, to asses therapeutic application of the humanized anti-CD33 mAb, as a proof of concept we have used two methods, first an ADC, an anti-human IgG (Fc) 2º Ab conjugated to MMAE, and second, 225 Ac-DOTA anti-human CD33 radioimmunotherapy (CD33-RIT). The in vitro cytotocxicity assay on MV4-11 cells using anti-CD33 mAb + 2º-ADC Ab (CD33-2º-ADC) was carried out as mentioned in methods. As control, 2º-ADC Ab alone (1 µg) was used, which showed no significant cell killing over untreated cells, while the same concentration of CD33-2º-ADC yielded ~55% cell killing (Fig. 6A) , and maximum (>95%) cell killing was anti-CD33 mAb-ADC to explore anti-CD33 immunotherapy using this humanized antibody and to monitor treatement response using anti-CD33 PET-CT imaging.
Discussion
We have developed a non-invasive anti-CD33 immunoPET-CT imaging method for the in vivo detection of AML disease with high sensitivity and specificity. Diagnostic and prognostic markers facilitate stratifying patients for treatment management. However, the current clinically approved diagnostic method is invasive, relying on single point (iliac crest) biopsies, which may 1) not always be representative of the actual disease state, and 2) limits the number of times it may be performed. Therefore, in leukemia non-invasive PET-imaging using PET tracers including F18-FDG (metabolic activity) and F18-FLT (cell proliferation) have been tested for diagnosis and monitoring treatment response (13) (14) (15) 16 ) . Although FDG-PET has shown some success in diagnosing extramedullary disease in AML (17) , it has also yielded highly inconsistent results because of changes in the metabolic activity of normal/tumor cells post treatment (18, 19) . Also, a recent study indicated that FLT-PET could identify the risk of early relapse in the spine prior to evidence of relapse by detection of minimal residual disease (MRD) (20) . However, these PET tracers are non-specific, they detect metabolically active or highly proliferating cells, which could be effected post treatment, unlike CD33-PET imaging which specifically detects cells expressing CD33, an accepted biomarker for AML. Studies have shown that even relapse AML blast post anti-CD33 therapy have CD33 expression (21, 22) . Therefore, CD33-based imaging is expected to improve detection of AML with high specificity in the whole body. This approach may also provide a blueprint for selecting biopsy sites (image-guided) that would be greatly useful for early detection and also in longitudinal monitoring of treatment response.
In this study, the 64 Cu-DOTA-anti-CD33 mAb PET was used to detect AML in vivo, showing very high specificity and sensitivity to CD33 + AML. The spatial information was achieved with whole body CT based 3D anatomical imaging. Notably, a spatial heterogeneity in the distribution of AML within the skeletal regions was observed, which would not be established with point biopsies. For example, CD33 activity was especially prominent in the L-spine and epiphysis/diaphysis of femurs, indicating a preferential skeletal niche for the disease at early stages. However, when the disease progresses, this spatial heterogeneity was reduced and the disease appeared to be more systemic. This finding suggests, contrary to previous beliefs that leukemia was a systemic disease, it appears that leukemia may be initiated in multiple preferential niches, characterized by multifocal disease before becoming more systemic. This imaging observation is warranting future investigation to understand the role of micro-enivironment favoring preferential disease localization. However, one small clinical study suggested that a heterogeneous distribution of leukemia may indicate resistance to chemotherapy, as shown through FLT-PET-based imaging of cell proliferation (23) . Therefore, future clinical studies may be designed to assess the prognostic value of this anti-CD33 oncoPET imaging. As immuno-PET combines the sensitivity and resolution of a PET imaging system with the high specificity of a monoclonal antibody, it may represent what is described as a "comprehensive immunohistochemical staining in vivo" (24) , therefore guiding precise locations for biopsies. Also, precisely specifying sites of disease could yield valuable information about the tumor in terms of location, phenotype, treatment susceptibility and response (25) . The spatial heterogeneity of leukemia also suggests caution should be taken when interpreting data from single-point biopsies.
Several investigational CD33-targeted therapeutics have been developed for AML (26) , including the recently FDA-approved anti-CD33 monoclonal antibody-drug conjugate gemtuzumab ozogamicin (GO, Mylotarg) (27) , bispecific antibodies such as CD33/CD3
antibodies (28), CD33/CD123-directed CAR T cells (29) . Although positive results have been reported from clinical trials of CD33-targeting drugs, dose limiting toxicities such as hepatotoxicities (30) during treatment are of concern. Therefore, an imaging tool as presented here would help determine optimal doses as well as monitoring treatment response non invasively, providing an opportunity to improve treatment efficacy while decreasing toxicities.
As the initial study was conducted using a murine anti-CD33 mAb, clone p67.6, for translational purposes, a humanized anti-CD33 monoclonal antibody (Hu-M195) was generated. We carried out preclinical PET-CT imaging using humanized anti-CD33 mAb and
showed that targeting was significantly improved over that of the murine version. Currently, cGMP grade mAb has been made for future phase I/II clinical trials. The Hu-M195 mAb labelled with 131 I has been shown to be useful for whole-body-gamma imaging of patients with myeloid leukemia (31) . However, this modality is planar or 2D imaging and is hence qualitative and lacks 3D quantitative information with spatial heterogeneity assessment of the disease. In contrast, 64 Cu-anti-CD33 PET-CT involves 3D imaging, which is quantitative and provides spatial information, resulting in a signifcanlty improved diagnostic imaging.
We further show that targeting CD33 using CD33-2º-ADC or CD33-RIT resulted in reduced disease burden, emphasizing its therapeutic potential. Such approaches are very effective against receptors like CD33, which is endocytosed after Ab binding, enabling the cytotoxic payload to internalize and result in cell killing (32, 33) . Futhermore, after CD33 antibody therapy, blasts in relapsed/refractory disease continue to express CD33, suggesting that AML cells may not use downregulation of CD33 as an epigenetic "escape mechanism" (22) , in contrast to the use of anti-CD38 mAb daratumumab which may result in relapse due to a CD38 -myeloma clone (34) . Therefore, CD33 PET imaging would be useful in monitoring treatment response post intervention, including CD33 targeted treatment. We would futher validate this approach preclinically using the primary humanized anti-CD33-ADC (which is in development) or RIT post CD33-directed therapy.
There are some limitations of this study. Although CD33 is expressed in all patients on at least a subset of AML blasts, high inter-patient variability in terms of level of expression (> 2 fold) is known (6, 35, 36) . This differential expression is not random but correlated with the presence of particular mutations; for example, very high CD33 expression has been shown in AML with NPM1 and FLT3/ITD mutations, whereas lower expression has been associated with core binding factor translocations (6, 36, 37) . A properly controlled imaging study with subset (mutation) analysis will be essential to understand whether specific mutations impact imaging intensity and/or heterogeneity.
In conclusion, to the best of our knowledge, this is the first preclinical report of an anti-CD33-PET-CT imaging modality to successfully detect AML in vivo. The imaging tool may be used curve showing sensitivity vs 100-specificity for the 64 Cu-DOTA-anti-CD33 imaging was generated using biodistribution data (n≥15 mice). The imaging method has a sensitivity of ~95.5% and specificity of 100 %. Therefore, this is a very reliable imaging method to detect AML. (B and C) A correlation curve for % engraftment vs % ID/g for femur and L-spine (n≥5 mice). A very high correlation was observed between leukemia engraftment and Cu-64-anti-CD33 activity in left femur (R² = 0.9854) and L-spine (R² = 0.8027). Engraftment was determined using flow cytometry. (D) A correlation curve for CD33 PET contour signal vs BLI signal (n≥5 mice). Strong correlation (R² = 0.9262) was seen between BLI signal vs PET signal; however, the spatial resolution was high in PET whereas in BLI it was poor. The data was assumed for Gaussian distribution, and Pearson's correlation coefficients were calculated using Prism software. The p value was calculated using two tailed t test and considered significant if <0.05. C) Three different activity of humanized 225 Ac-DOTA-anti-CD33 ( 100nci, 200nci, 300nci) was injected into mice bearing AML. All activity significantly reduced leukemia burden (p<0.00001) as measured by BLI intensity ( photons/s) at 14 days post intervention in comparison to untreated AML bearing mice (n=5). Statistical significance was determined using ANOVA and considered significant when <0.05.
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